

Michael C Roach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/935232/publications.pdf>

Version: 2024-02-01

36
papers

1,647
citations

471371

17
h-index

414303

32
g-index

36
all docs

36
docs citations

36
times ranked

2317
citing authors

#	ARTICLE	IF	CITATIONS
1	Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. <i>Advances in Radiation Oncology</i> , 2021, 6, 100506.	0.6	70
2	Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program. <i>Brachytherapy</i> , 2021, 20, 237-247.	0.2	10
3	Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100602.	0.6	9
4	Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT. <i>Radiotherapy and Oncology</i> , 2020, 142, 230-235.	0.3	27
5	Long-Term Outcomes with 3-Dimensional Conformal External Beam Accelerated Partial Breast Irradiation. <i>Practical Radiation Oncology</i> , 2020, 10, e128-e135.	1.1	3
6	Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 32-35.	0.9	6
7	Adherence of US Insurance Payer Policies to the American Society of Radiation Oncology Stereotactic Radiosurgery Model Policy. <i>Practical Radiation Oncology</i> , 2020, 10, e250-e254.	1.1	0
8	Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC. <i>Radiotherapy and Oncology</i> , 2020, 150, 206-210.	0.3	5
9	Anatomical Adaptation—Early Clinical Evidence of Benefit and Future Needs in Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2019, 29, 274-283.	1.0	17
10	Differences in United States Insurance Payer Policies and American Society for Radiation Oncology's (ASTRO) Model Policy on Stereotactic Body Radiation Therapy (SBRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 740-744.	0.4	4
11	Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model. <i>Breast Journal</i> , 2019, 25, 363-372.	0.4	6
12	Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. <i>Cancer Medicine</i> , 2019, 8, 2123-2132.	1.3	243
13	Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 1-6.	0.9	0
14	Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e83-e89.	1.1	4
15	Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. <i>Advances in Radiation Oncology</i> , 2019, 4, 201-209.	0.6	133
16	Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers. <i>Clinical Lung Cancer</i> , 2019, 20, 107-116.	1.1	19
17	MRI at the Time of External Beam Treatment. , 2019, , 169-188.		1
18	Natural Disasters and the Importance of Minimizing Subsequent Radiation Therapy Interruptions for Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 836-837.	0.4	10

#	ARTICLE	IF	CITATIONS
19	Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule. <i>Practical Radiation Oncology</i> , 2018, 8, 404-413.	1.1	13
20	Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2465-S2473.	0.6	32
21	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. <i>Translational Lung Cancer Research</i> , 2018, 8, 107-115.	1.3	40
22	Combining immunotherapy with radiation therapy in thoracic oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S2492-S2507.	0.6	16
23	Stereotactic Body Radiation Therapy for Central Early-Stage NSCLC: Results of a Prospective Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1727-1732.	0.5	50
24	A novel MRI segmentation method using a CNN-based correction network for MRI-guided adaptive radiotherapy. <i>Medical Physics</i> , 2018, 45, 5129-5137.	1.6	109
25	Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 498-504.	0.3	75
26	Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospital-based analysis of patterns of care, RT fractionation scheme, and overall survival. <i>Cancer Medicine</i> , 2018, 7, 4240-4250.	1.3	10
27	Practical Implications of Ferromagnetic Artifacts in Low-field MRI-guided Radiotherapy. <i>Cureus</i> , 2018, 10, e2359.	0.2	4
28	Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 295-301.	1.1	339
29	Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system. <i>Advances in Radiation Oncology</i> , 2017, 2, 485-493.	0.6	128
30	Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database. <i>Cancer Medicine</i> , 2017, 6, 2886-2896.	1.3	46
31	Adaptive anatomical preservation optimal denoising for radiation therapy daily MRI. <i>Journal of Medical Imaging</i> , 2017, 4, 1.	0.8	0
32	It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. <i>Practical Radiation Oncology</i> , 2016, 6, 12-18.	1.1	26
33	Treatment of Peripheral Non-Small Cell Lung Carcinoma with Stereotactic Body Radiation Therapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1261-1267.	0.5	19
34	FDG-PET Assessment of the Effect of Head and Neck Radiotherapy on Parotid Gland Glucose Metabolism. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 321-326.	0.4	36
35	Analysis of Pretreatment FDG-PET SUV Parameters in Head-and-Neck Cancer: Tumor SUV _{mean} Has Superior Prognostic Value. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 548-553.	0.4	118
36	Phosphoinositide Kinase-3 Status Associated With Presence or Absence of Human Papillomavirus in Head and Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S98-S101.	0.4	19